| Repurposing of FDA‐approved drugs against active site and potential allosteric drug‐binding sites of COVID‐19 main protease M Yuce, E Cicek, T Inan, AB Dag, O Kurkcuoglu, FA Sungur Proteins: Structure, Function, and Bioinformatics 89 (11), 1425-1441, 2021 | 48 | 2021 |
| Exploring allosteric signaling in the exit tunnel of the bacterial ribosome by molecular dynamics simulations and residue network model P Guzel, HZ Yildirim, M Yuce, O Kurkcuoglu Frontiers in Molecular Biosciences 7, 586075, 2020 | 16 | 2020 |
| Exploring species-specific inhibitors with multiple target sites on S. aureus pyruvate kinase using a computational workflow M Yuce, Z Sarica, B Ates, O Kurkcuoglu Journal of Biomolecular Structure and Dynamics 41 (8), 3496-3510, 2023 | 4 | 2023 |
| Exploring Druggable Binding Sites on the Class A GPCRs Using the Residue Interaction Network and Site Identification by Ligand Competitive Saturation T Inan, M Yuce, AD MacKerell Jr, O Kurkcuoglu ACS omega 9 (38), 40154-40171, 2024 | 2 | 2024 |
| Live Cell Imaging of Peptide Uptake Using a Microfluidic Platform M Yuce, E Ozkirimli, B Sariyar Akbulut, K Ulgen International Journal of Peptide Research and Therapeutics 27 (3), 2003-2013, 2021 | 1 | 2021 |
| A computational workflow to determine drug candidates alternative to aminoglycosides targeting the decoding center of E. coli ribosome M Yuce, B Ates, NI Yasar, FA Sungur, O Kurkcuoglu Journal of Molecular Graphics and Modelling 131, 108817, 2024 | | 2024 |
